QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

Dominari (DOMH) Competitors

$2.10
-0.04 (-1.87%)
(As of 02/28/2024 ET)

DOMH vs. NXGL, AIKI, BCDA, MEDS, ELAB, NHWK, MBIO, GHSI, HEPA, and OSA

Should you be buying Dominari stock or one of its competitors? The main competitors of Dominari include NEXGEL (NXGL), AIkido Pharma (AIKI), BioCardia (BCDA), TRxADE HEALTH (MEDS), Elevai Labs (ELAB), NightHawk Biosciences (NHWK), Mustang Bio (MBIO), Guardion Health Sciences (GHSI), Hepion Pharmaceuticals (HEPA), and ProSomnus (OSA). These companies are all part of the "medical" sector.

Dominari vs.

NEXGEL (NASDAQ:NXGL) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, community ranking, earnings and institutional ownership.

2.8% of NEXGEL shares are owned by institutional investors. Comparatively, 11.9% of Dominari shares are owned by institutional investors. 27.2% of NEXGEL shares are owned by insiders. Comparatively, 9.7% of Dominari shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NEXGEL received 1 more outperform votes than Dominari when rated by MarketBeat users.

CompanyUnderperformOutperform
NEXGELOutperform Votes
1
50.00%
Underperform Votes
1
50.00%
DominariN/AN/A

NEXGEL has higher revenue and earnings than Dominari.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$2.05M6.67-$4.75M-$0.48-4.98
DominariN/AN/A-$22.11MN/AN/A

NEXGEL has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Dominari has a net margin of 0.00% compared to Dominari's net margin of -76.64%. NEXGEL's return on equity of -35.32% beat Dominari's return on equity.

Company Net Margins Return on Equity Return on Assets
NEXGEL-76.64% -38.69% -25.90%
Dominari N/A -35.32%-33.02%

In the previous week, NEXGEL had 2 more articles in the media than Dominari. MarketBeat recorded 4 mentions for NEXGEL and 2 mentions for Dominari. NEXGEL's average media sentiment score of 1.43 beat Dominari's score of 1.29 indicating that Dominari is being referred to more favorably in the news media.

Company Overall Sentiment
NEXGEL Positive
Dominari Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Dominari
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Summary

NEXGEL beats Dominari on 6 of the 11 factors compared between the two stocks.


Get Dominari News Delivered to You Automatically

Sign up to receive the latest news and ratings for DOMH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DOMH vs. The Competition

MetricDominariSecurity brokers & dealers IndustryMedical SectorNASDAQ Exchange
Market Cap$11.24M$21.39B$4.97B$7.45B
Dividend YieldN/A2.82%2.90%3.88%
P/E RatioN/A12.54222.2916.74
Price / SalesN/A4.723,035.5764.64
Price / CashN/A41.3994.9854.63
Price / Book0.162.034.464.66
Net Income-$22.11M$860.93M$112.66M$210.55M
7 Day Performance3.96%1.97%5.18%2.49%
1 Month Performance-4.55%1.35%13.06%4.77%
1 Year Performance-47.76%77.17%12.02%7.46%

Dominari Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGL
NEXGEL
0.7709 of 5 stars
$2.01
-6.1%
N/A+61.5%$11.49M$3.53M-4.1912Gap Down
AIKI
AIkido Pharma
0 of 5 stars
$2.12
+1.0%
N/A-41.2%$11.63M$10,000.00-0.554Gap Down
BCDA
BioCardia
2.3202 of 5 stars
$0.45
flat
$4.00
+788.9%
-76.6%$11.66M$1.35M-0.7330Short Interest ↑
Gap Up
MEDS
TRxADE HEALTH
2.7205 of 5 stars
$9.09
+98.0%
$26.25
+188.8%
+50.9%$11.00M$11.45M-1.3133Positive News
Gap Up
High Trading Volume
ELAB
Elevai Labs
0 of 5 stars
$0.74
+8.8%
N/AN/A$11.81M$1.15M0.0016Short Interest ↓
Positive News
Gap Up
NHWK
NightHawk Biosciences
0 of 5 stars
$0.41
+9.0%
N/A-54.6%$10.78M$6.38M-0.2177News Coverage
MBIO
Mustang Bio
3.3662 of 5 stars
$1.29
flat
$17.25
+1,237.2%
-82.5%$11.89MN/A-0.16113Positive News
Gap Down
GHSI
Guardion Health Sciences
0 of 5 stars
$8.41
flat
N/A+20.4%$10.77M$11.05M0.0012Short Interest ↑
HEPA
Hepion Pharmaceuticals
0.5975 of 5 stars
$2.48
-3.1%
N/A-85.1%$10.76MN/A0.0025Upcoming Earnings
Short Interest ↑
Positive News
OSA
ProSomnus
3.2875 of 5 stars
$0.64
-9.8%
$2.33
+261.8%
-87.6%$10.58M$19.39M0.00129Short Interest ↓

Related Companies and Tools

This page (NASDAQ:DOMH) was last updated on 2/28/2024 by MarketBeat.com Staff